Hypertrophic cardiomyopathy is a heterogeneous disorder, both from a phenotypic and genotypic standpoint. Predicting which pediatric patients are at greatest risk for disease progression and sudden death may be very difficult clinically. In the future, genetic analysis may become more clinically useful in...
Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population J Am Heart Assoc, 3 (2014), p. e001002 CrossrefGoogle Scholar 14 I. Olivotto, M.S. Maron, A.S. Adabag, et al. Gender-related differences in the clinical pres...
Hypertrophic cardiomyopathy accounts for 36% of deaths in athletes younger than 35 (most common cause of sudden death in this age group). Most sudden deaths are due to ventricular fibrillation (VF) or ventricular tachycardia (VT) (see fig. 61). These patients should avoid competitive sports bec...
et al. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med.2000;342:1778-1785.Google Scholar 42. Elliott PM, Gimeno Blanes JR. et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with ...
Prevention of Sudden Death Among Patients With Hypertrophic Cardiomyopathy (HCM) View LargeDownload A, Risk stratification model used to identify highest-risk patients who may be candidates for primary prevention of sudden death by use of the implantable cardioverter-defibrillator (ICD). Risk markers ...
Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Youthful age has been considered the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of the possibility of su...
Hypertrophic cardiomyopathy (HCM) remains the most common cardiomyopathy in humans and cats with few preclinical pharmacologic interventional studies. Small-molecule sarcomere inhibitors are promising novel therapeutics for the management of obstructive HCM (oHCM) patients and have shown efficacy in left ven...
This study aims to explore the correlation between PET and CMR in integrated [ 68 Ga]Ga-FAPI-04 PET/CMR multimodal imaging and its value in the diagnosis and risk assessment of hypertrophic cardiomyopathy (HCM).This study included 20 HCM patients and 11 age- and gender-matched controls. PET...
hypertrophic cardiomyopathy is distinguished from dilated cardiomyopathy based on the protein-protein interaction network pattern. Within the hypertrophic cardiomyopathy cohort, the patient-specific networks are variable in complexity, and enriched for 30 endophenotypes. The cardiac Janus kinase 2-Signal Transdu...
Table 5. General Considerations for Management of Pregnant Women With Hypertrophic Cardiomyopathy Assessment of symptoms and functional status before pregnancy Determine the degree of LVOT obstruction at rest and with Valsalva maneuver (by echocardiogram) to identify those with severe obstruction Risk stratif...